In utero allotransplantation of retrovirally transduced fetal hepatocytes in primates: Feasibility and short-term follow-up

• Published in: The Journal of maternal-fetal medicine 1998, Vol.7 (6), p.296-303
• Main Authors: Andreoletti, Marion, LePercq, Jacques, Loux, Nathalie, Beaudoin, Sylvie, Sacquin, Paul, Borgnon, Joséphine, Nguyen, Tuan, Mahieu, Dominique, Toubas, Françoise, Di Rico, Virginie, Farge, Denis, Franco, Dominique, Briand, Pascale, Hamza, Jamil, Capron, Frédérique, Bargy, Frédéric, Weber, Anne
• Format: Article
• Language: English
• Subjects: allotransplantation; fetal hepatocytes; in utero; primates; retroviral transduction
• ISSN: 1476-7058; 1057-0802; 1476-4954; 1520-6661
• DOI: 10.3109/14767059809020462

In utero allotransplantation of fetal hepatocytes into a preimmune fetus could be used in early treatment of many inherited hepatic metabolic diseases. This study was designed to assess the tolerance to hepatocyte transplantation and to test the feasability and toxicity of such an injection in a primate model. Fetal hepatocytes were obtained from two 120-day-old Macaca mulatta fetuses and cryopreserved. They were thawed, cultured in vitro, and transduced with a recombinant retrovirus expressing β-galactosidase. Transduction efficiency was 75-85%. Three unrelated fetuses (90, 100, and 104 days old) were each given 1-2 107 transduced cells via the umbilical vein. This caused vasospasm and severe bradycardia. Two fetuses died in the 48 hours after transplantation; the third survived and was killed at the end of gestation. No evidence of the infused cells was found. Three fetuses (90 days old) were, therefore, given 3-4 107 hepatocytes by direct intrahepatic injection. All the fetuses survived without side effect. Donor cells were not apparent from histochemical staining and PCR reactions. There was no evidence of inflammatory reaction. These findings indicate that the protocole could be improved by increasing the number of transplanted cells and using specific hepatic promoters in the retroviral vectors to achieve an effective postnatal chimerism. Contract grant sponsor: INSERM (Poste d'Accueil to M.A.); Contract grant sponsor: Institut Electricite Sante (to N.L.); Contract grant sponsor: INSERM; Contract grant number: 920303; Contract grant sponsor: Caisse Nationale d'Assurance Maladie des Travailleurs Salariés; Contract grant number: AM088; Contract grant sponsor: Ministère de la Recherche et de la Technologie; Contract grant sponsor: University René Descartes Paris V; Contract grant sponsor: University Paris XI; Contract grant sponsor: Fondation pour la Recherche Médicale.